Concerns about coronavirus news out of China may have moved some vaccine-maker and travel stocks Friday.

Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

Moderna (MRNA) has disclosed a new risk, in the Sales & Marketing category. Moderna faces significant commercial challenges, particularly in ...

Moderna secures a multi-year agreement to supply its COVID-19 vaccine to 17 European countries, including Norway and North Macedonia. Vaccine formats include prefilled syringes, reducing ...

Under the resulting agreement, 17 participating countries can access Moderna's mRNA COVID-19 vaccine for up to four years. "This agreement presents an opportunity for Moderna to support and ...

US gives conditional nod to Zoetis' bird flu vaccine for poultry Healthcare & Pharmaceuticalscategory· February 14, 2025 Moderna said on Friday that the U.S. FDA paused a late-stage trial of its ...

Following four straight sessions of gains, Moderna (NASDAQ:MRNA) shares continued to trade higher in the premarket on Friday after the company received a tender to supply its COVID-19 vaccine in ...

Moderna, Inc. (NASDAQ:MRNA) today announced that it has been awarded a tender for the supply of its mRNA COVID-19 vaccine in the European Union (EU), Norway and North Macedonia. Under the ...

(Reuters) -Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a rare neurological side effect was reported. The trial of the ...